Please assess the completion status of the following clinical trial:

Trial Title: The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD~* FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post- bronchodilator FEV1/FVC \< 70%~Exclusion Criteria:~* Any clinically relevant abnormal findings at screening examinations~* Any clinically significant disease or disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZD9164 100 mcg First, then Placebo for Spririva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- AZD9164 400 mcg First, then Placebo for Spiriva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- AZD9164 1200 mcg First, then Placebo for Spiriva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- Spiriva 18 mcg First, then Placebo for AZD9164 (Type: ACTIVE_COMPARATOR): 1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
- Placebo for Spiriva First, then Placebo for AZD9164 (Type: PLACEBO_COMPARATOR): 1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)

Based on this trial design, predict the completion outcome and termination type (if applicable).